Cat. No.: HY-12823

BLU9931

10 Cited Publications

Customer Review

Based on 10 publication(s) in Google Scholar

BLU9931 is a potent, highly selective, and irreversible fibroblast growth factor receptor 4 (FGFR4) inhibitor with an IC₅₀ of 3 nM and a K_d of 6 nM. BLU9931 has significant antitumor activity.

For research use only. We do not sell to patients.

Purity: 99.97%
CAS No.: 1538604-68-0
Formula: C₂₆H₂₂Cl₂N₄O₃
Molecular Weight:509.38

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

BLU9931 Chemical Structure

CAS No.: 1538604-68-0

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (10)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target^[1]

FGFR1

591 nM (IC₅₀)

FGFR2

493 nM (IC₅₀)

FGFR3

150 nM (IC₅₀)

FGFR4

3 nM (IC₅₀)

Cellular Effect

Cell Line	Type	Value	Description	References
BaF3	IC₅₀	>5000 nM Compound: BLU9931	Antiproliferative activity against mouse BaF3 cells incubated for 72 hrs by CCK-8 assay Antiproliferative activity against mouse BaF3 cells incubated for 72 hrs by CCK-8 assay	[PMID: 38432058]
BaF3	IC₅₀	1.9 nM Compound: BLU9931	Antiproliferative activity against mouse BaF3 cells expressing FGFR4 incubated for 72 hrs by CCK-8 assay Antiproliferative activity against mouse BaF3 cells expressing FGFR4 incubated for 72 hrs by CCK-8 assay	[PMID: 38432058]
BaF3	IC₅₀	5.12 nM Compound: BLU9931	Antiproliferative activity against mouse BaF3 transfected with FGFR4 assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay Antiproliferative activity against mouse BaF3 transfected with FGFR4 assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 37556948]
Epithelial cell	IC₅₀	18.42 μM Compound: BLU9931	Antiproliferative activity against human Intestinal epithelial cell assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human Intestinal epithelial cell assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 37556948]
HCT-116	IC₅₀	8.89 μM Compound: BLU9931	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 37556948]
Hep 3B2	EC₅₀	62 nM Compound: BLU9931; 2	Antiproliferative activity against human Hep3B cells measured after 4 days by Celltiter-glo based luminescent assay Antiproliferative activity against human Hep3B cells measured after 4 days by Celltiter-glo based luminescent assay	[PMID: 38604131]
Hep 3B2	IC₅₀	0.058 μM Compound: 1a; BLU9931	Antiproliferative activity against human Hep3B cells assessed as inhibition of cell growth incubated for 5 days by SRB assay Antiproliferative activity against human Hep3B cells assessed as inhibition of cell growth incubated for 5 days by SRB assay	[PMID: 33859803]
Hep 3B2	IC₅₀	0.288 μM Compound: BLU9931	Antiproliferative activity against human Hep3B cells assessed as reduction in cell viability incubated for 72 hrs by Cell Titer-Glo assay Antiproliferative activity against human Hep3B cells assessed as reduction in cell viability incubated for 72 hrs by Cell Titer-Glo assay	[PMID: 33218898]
Hep 3B2	IC₅₀	550 nM Compound: 5	Cytotoxicity against human Hep 3B2.1-7 cells harboring FGF19/FGFR4 assessed as inhibition of cell growth Cytotoxicity against human Hep 3B2.1-7 cells harboring FGF19/FGFR4 assessed as inhibition of cell growth	[PMID: 35119278]
Hep 3B2	IC₅₀	72 nM Compound: 15; BLU9931	Antiproliferative activity against human Hep3B cells incubated for 72 hrs by CCK8 assay Antiproliferative activity against human Hep3B cells incubated for 72 hrs by CCK8 assay	[PMID: 33030342]
HepG2	IC₅₀	5.458 μM Compound: BLU9931	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 33618175]
Huh-7	IC₅₀	0.929 μM Compound: BLU9931	Antiproliferative activity against human Huh-7 cells assessed as inhibition of cell proliferation measured after 72 hrs by SRB assay Antiproliferative activity against human Huh-7 cells assessed as inhibition of cell proliferation measured after 72 hrs by SRB assay	[PMID: 34488024]
Huh-7	IC₅₀	191 nM Compound: 5; BLU9931	Antiproliferative activity against FGFR4 overexpressing human Huh-7 cells assessed as inhibition of cell growth by SRB assay Antiproliferative activity against FGFR4 overexpressing human Huh-7 cells assessed as inhibition of cell growth by SRB assay	[PMID: 38706130]
Huh-7	IC₅₀	327 nM Compound: 2; BLU9931	Inhibition of cell proliferation in human Huh-7 cells incubated for 72 hrs by Cell Titer-Glo luminescent assay Inhibition of cell proliferation in human Huh-7 cells incubated for 72 hrs by Cell Titer-Glo luminescent assay	[PMID: 35549181]
Huh-7	IC₅₀	5.386 μM Compound: BLU9931	Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 33618175]
Huh-7	IC₅₀	84 nM Compound: 15; BLU9931	Antiproliferative activity against human Huh-7 cells incubated for 72 hrs by CCK8 assay Antiproliferative activity against human Huh-7 cells incubated for 72 hrs by CCK8 assay	[PMID: 33030342]
MCF7	IC₅₀	2.34 μM Compound: 1; BLU9931	Antiproliferative activity against human MCF7 cells expressing low levels of FGFR4 after 72 hrs by CCK8 assay Antiproliferative activity against human MCF7 cells expressing low levels of FGFR4 after 72 hrs by CCK8 assay	[PMID: 28523108]
MDA-MB-231	IC₅₀	3.76 μM Compound: 1; BLU9931	Antiproliferative activity against human MDA-MB-231 cells expressing low levels of FGFR4 after 72 hrs by CCK8 assay Antiproliferative activity against human MDA-MB-231 cells expressing low levels of FGFR4 after 72 hrs by CCK8 assay	[PMID: 28523108]
MDA-MB-435	IC₅₀	0.039 μM Compound: 1a; BLU9931	Antiproliferative activity against human MDA-MB-453 cells assessed as inhibition of cell growth incubated for 5 days by SRB assay Antiproliferative activity against human MDA-MB-453 cells assessed as inhibition of cell growth incubated for 5 days by SRB assay	[PMID: 33859803]
MDA-MB-453	IC₅₀	0.32 μM Compound: 1; BLU9931	Antiproliferative activity against human MDA-MB-453 cells harboring FGFR4 Y367C mutant after 72 hrs by CCK8 assay Antiproliferative activity against human MDA-MB-453 cells harboring FGFR4 Y367C mutant after 72 hrs by CCK8 assay	[PMID: 28523108]
MDA-MB-453	IC₅₀	120 nM Compound: 5	Cytotoxicity against human MDA-MB-453 cells harboring FGF19/FGFR4 assessed as inhibition of cell growth Cytotoxicity against human MDA-MB-453 cells harboring FGF19/FGFR4 assessed as inhibition of cell growth	[PMID: 35119278]
MDA-MB-453	IC₅₀	29 nM Compound: 2; BLU9931	Inhibition of cell proliferation in human MDA-MB-453 cells incubated for 72 hrs by Cell Titer-Glo luminescent assay Inhibition of cell proliferation in human MDA-MB-453 cells incubated for 72 hrs by Cell Titer-Glo luminescent assay	[PMID: 35549181]
NCI-H1299	IC₅₀	1.03 μM Compound: 1a; BLU9931	Antiproliferative activity against human H1299 cells assessed as inhibition of cell growth incubated for 5 days by SRB assay Antiproliferative activity against human H1299 cells assessed as inhibition of cell growth incubated for 5 days by SRB assay	[PMID: 33859803]
NCI-H1581	IC₅₀	>43.3 μM Compound: 5	Cytotoxicity against human NCI-H1581 cells harboring FGF19/FGFR4 assessed as inhibition of cell growth Cytotoxicity against human NCI-H1581 cells harboring FGF19/FGFR4 assessed as inhibition of cell growth	[PMID: 35119278]
RKO	IC₅₀	19.67 μM Compound: BLU9931	Antiproliferative activity against human RKO cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human RKO cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 37556948]
SMMC-7721	IC₅₀	6.617 μM Compound: BLU9931	Cytotoxicity against human SMMC-7721 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human SMMC-7721 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 33618175]
SW480	IC₅₀	12.72 μM Compound: BLU9931	Antiproliferative activity against human SW480 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human SW480 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 37556948]

In Vitro

BLU9931 inhibits proliferation of HCC cell lines that express an intact FGFR4 signaling complex, with EC₅₀s of 0.07 μM, 0.11 μM and 0.02 μM for Hep 3B, HuH7 and JHH7 cells, respectively^[1].
BLU9931 (0.3-300 nM; 1 hour; MDA-MB-453 and Hep 3B cells) treatment demonstrates potent, dose-dependent reduction of phosphorylation of FGFR4 signaling pathway components, including fibroblast growth factor receptor substrate 2 (FRS2), MAPK, and AKT in MDA-MB-453 cells. BLU9931 shows dose-dependent inhibition of the signaling cascade downstream of FGFR4. BLU9931 exhibits potent inhibition of phosphorylation of the FGFR4 pathway components in Hep 3B cells. BLU9931 treatment leads to induction of caspase-3/7 activity, indicative of induction of apoptosis that results in inhibition of signaling downstream of FGFR4^[1].
BLU9931 (100 nM; 0 -24 hours; Hep 3B cells) treatment increases CYP7A1 mRNA expression and the expression of the proliferative marker EGR1 is inhibited^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:

MDA-MB-453 and Hep 3B cells
Concentration:

0.3 nM, 1 nM, 3 nM, 10 nM, 30 nM, 100 nM, 300 nM
Incubation Time:

1 hour
Result:

Demonstrated potent, dose-dependent reduction of phosphorylation of FGFR4 signaling pathway components, including fibroblast growth factor receptor substrate 2 (FRS2), MAPK, and AKT in MDA-MB-453 and Hep 3B cells.

RT-PCR^[1]

Cell Line:

Hep 3B cells
Concentration:

100 nM
Incubation Time:

0 hour, 4 hours, 8 hour, 24 hours
Result:

Increased CYP7A1 mRNA expression. And the expression of the proliferative marker EGR1 was inhibited.

In Vivo

BLU9931 (10-100 mg/kg; oral administration; twice every day; for 21 days; mice) treatment demonstrates antitumor activity in HCC xenograft models^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Mice injected with Hep 3B cells^[1]
Dosage:

10 mg/kg, 30 mg/kg or 100 mg/kg
Administration:

Oral administration; twice every day; for 21 days
Result:

Resulted in dose-dependent growth inhibition of Hep 3B tumors. Prevented weight loss in a dose-dependent manner.

Chemical Information

CAS No. 1538604-68-0
Appearance Solid
Molecular Weight 509.38
Formula C₂₆H₂₂Cl₂N₄O₃
Color White to light yellow
SMILES

C=CC(NC1=CC=CC(C)=C1NC2=NC=C3C=C(C4=C(Cl)C(OC)=CC(OC)=C4Cl)C=CC3=N2)=O
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (10)

All WB

Sort by:

Journal Impact Factor

Nat Commun

Human iPSC-based Modeling of Pulmonary Fibrosis Reveals p300/CBP Inhibition Suppresses Alveolar Transitional Cell State. [Abstract]

2026 Feb 12;17(1):1214. PMID: 41680175
Theranostics

FGF19/SOCE/NFATc2 signaling circuit facilitates the self-renewal of liver cancer stem cells. [Abstract]

2021 Mar 5;11(10):5045-5060. PMID: 33754043
Int J Biol Sci

Aberrant FGFR4 signaling worsens nonalcoholic steatohepatitis in FGF21KO mice. [Abstract]

2021 Jun 22;17(10):2576-2589. PMID: 34326695
Clin Transl Med

Spliceosomal profiling identifies EIF4A3 as a novel oncogene in hepatocellular carcinoma acting through the modulation of FGFR4 splicing. [Abstract]

2022 Nov;12(11):e1102. PMID: 36419260
Eur J Med Chem

Design, synthesis, and biological evaluation of 1,6-naphthyridine-2-one derivatives as novel FGFR4 inhibitors for the treatment of colorectal cancer. [Abstract]

2023 Nov 5:259:115703. PMID: 37556948
Commun Biol

Wnt/FGF20 signaling axis promotes migration of proximal blastema cell during tail regeneration of Gekko japonicus. [Abstract]

2025 Dec 15. PMID: 41398307
Int J Oncol

Combination of FGFR4 inhibitor Blu9931 and 5-fluorouracil effects on the biological characteristics of colorectal cancer cells. [Abstract]

2017 Nov;51(5):1611-1620. PMID: 29048661

BLU9931 purchased from MedChemExpress. Usage Cited in: Int J Oncol. 2017 Nov;51(5):1611-1620. [Abstract]

Western blot detection of the expression of related molecules including signal pathway (STAT3), apoptosis (cleaved caspase‑3), cell cycle (cyclin D1 and P27^kip1) and epithelial-mesenchymal transition (E-cadherin and vimentin) in HCT116 and SW620 cells when treated by the single and combination of 5-FU and Blu9931.
J Biol Chem

MAP3K4 promotes fetal and placental growth by controlling the receptor tyrosine kinases IGF1R/IR and Akt signaling pathway. [Abstract]

2022 Sep;298(9):102310. PMID: 35921893
Clin Immunol

Inhibition of neutrophil extracellular traps via the FGF19/ERK/IL-8 axis enhances immune therapy in MSS colorectal cancer. [Abstract]

2026 Apr:284:110664. PMID: 41565192
University of Auckland

2025.

Solvent & Solubility

In Vitro:

DMSO : 83.33 mg/mL (163.59 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.9632 mL

9.8159 mL

19.6317 mL

5 mM

0.3926 mL

1.9632 mL

3.9263 mL

10 mM

0.1963 mL

0.9816 mL

1.9632 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (4.08 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (4.08 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (4.08 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (279 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Hagel M, et al. First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway. Cancer Discov. 2015 Apr;5(4):424-37. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.9632 mL	9.8159 mL	19.6317 mL	49.0793 mL
	5 mM	0.3926 mL	1.9632 mL	3.9263 mL	9.8159 mL
	10 mM	0.1963 mL	0.9816 mL	1.9632 mL	4.9079 mL
	15 mM	0.1309 mL	0.6544 mL	1.3088 mL	3.2720 mL
	20 mM	0.0982 mL	0.4908 mL	0.9816 mL	2.4540 mL
	25 mM	0.0785 mL	0.3926 mL	0.7853 mL	1.9632 mL
	30 mM	0.0654 mL	0.3272 mL	0.6544 mL	1.6360 mL
	40 mM	0.0491 mL	0.2454 mL	0.4908 mL	1.2270 mL
	50 mM	0.0393 mL	0.1963 mL	0.3926 mL	0.9816 mL
	60 mM	0.0327 mL	0.1636 mL	0.3272 mL	0.8180 mL
	80 mM	0.0245 mL	0.1227 mL	0.2454 mL	0.6135 mL
	100 mM	0.0196 mL	0.0982 mL	0.1963 mL	0.4908 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

BLU9931

Kinase Inhibitor Library

Protein Tyrosine Kinase Compound Library

Anti-Cancer Compound Library

Covalent Screening Library

Reprogramming Compound Library

Chemical Probe Library

Anti-Lung Cancer Compound Library

Angiogenesis-Related Compound Library

Targeted Diversity Library

Anti-Liver Cancer Compound Library

Anti-Prostate Cancer Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Highly Selective Inhibitors Library

Cytokine Inhibitors Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Covalent Screening Library Plus

Bioactive Compound Library

Anti-Fibrosis Compound Library

Anti-Brain Cancer Compound Library

Protein Kinase Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

Publications Citing Use of MedChemExpress (MCE) BLU9931

Biological Activity

Chemical Information

Publications (10)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

BLU9931

Kinase Inhibitor Library

Protein Tyrosine Kinase Compound Library

Anti-Cancer Compound Library

Covalent Screening Library

Reprogramming Compound Library

Chemical Probe Library

Anti-Lung Cancer Compound Library

Angiogenesis-Related Compound Library

Targeted Diversity Library

Anti-Liver Cancer Compound Library

Anti-Prostate Cancer Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Highly Selective Inhibitors Library

Cytokine Inhibitors Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Covalent Screening Library Plus

Bioactive Compound Library

Anti-Fibrosis Compound Library

Anti-Brain Cancer Compound Library

Protein Kinase Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

Publications Citing Use of MedChemExpress (MCE) BLU9931

Biological Activity

Chemical Information

Publications (10)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

BLU9931 Related Classifications

HY-12823 Related Classifications